Entrada director granted 19,000 options at $5.97

Entrada Therapeutics director Mary Thistle received a stock option grant covering 19,000 shares of common stock.

Rhea-AI Filing Summary

Entrada Therapeutics director Mary Thistle received a stock option grant covering 19,000 shares of common stock. The option has an exercise price of $5.97 per share and expires on June 10, 2036. According to the terms, the award vests on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders. This is a compensation-related grant rather than an open-market trade.

Insider Trade Summary

Grant/Award: 19,000 shares

Grant/Award 1 txn

Insider Thistle Mary

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Key Figures

Option grant size: 19,000 options Exercise price: $5.97 per share Expiration date: June 10, 2036 +2 more

5 metrics

Option grant size 19,000 options Stock Option (Right to Buy) granted to director

Exercise price $5.97 per share Conversion or exercise price of stock option

Expiration date June 10, 2036 Option expiration for director grant

Shares underlying options 19,000 shares Underlying Entrada Therapeutics common stock

Vesting condition Earlier of 1-year from June 10, 2026 or next annual meeting Time-based vesting schedule from footnote

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.9700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable on the earlier of"

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Entrada Therapeutics (TRDA) director Mary Thistle report in this Form 4?

Mary Thistle reported receiving a stock option grant for 19,000 shares of Entrada Therapeutics common stock. The award is a compensation-related option, not an open-market transaction, and was reported as an acquisition under transaction code A on the Form 4.

What are the key terms of Mary Thistle’s 19,000-share option grant at Entrada Therapeutics (TRDA)?

The option covers 19,000 shares of common stock at a $5.97 exercise price and expires June 10, 2036. It was granted at no cost per option share, reflecting a typical director compensation award rather than a purchase in the open market.

How and when do Mary Thistle’s Entrada Therapeutics (TRDA) stock options vest?

The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada Therapeutics’ next annual meeting of stockholders. This time-based vesting ties the director’s compensation to continued service over the coming year.

Did Mary Thistle buy or sell Entrada Therapeutics (TRDA) shares in the market?

The filing shows no market buy or sell; it reports only a grant of stock options. The transaction is coded as an acquisition (A) reflecting a compensation award, with a zero-dollar transaction price per option rather than an open-market trade price.

How many Entrada Therapeutics (TRDA) options does Mary Thistle hold after this grant?

After this reported transaction, Mary Thistle holds 19,000 stock options directly as reflected in the Form 4. These options, if vested and exercised at $5.97 per share, would convert into an equal number of Entrada Therapeutics common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thistle Mary

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.97	06/10/2026		A		19,000		(1)	06/10/2036	Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)